Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) stock jumped 4.42% on Monday to $9.45 against a previous-day closing price of $9.05. With 9.63 million shares changed hands, the volume of the stock remained heavier than its average volume of 8.31 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $9.48 whereas the lowest price it dropped to was $9.04. The 52-week range on TEVA shows that it touched its highest point at $11.44 and its lowest point at $7.09 during that stretch. It currently has a 1-year price target of $10.62. Beta for the stock currently stands at 1.16.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TEVA was up-trending over the past week, with a rise of 7.14%, but this was up by 16.38% over a month. Three-month performance dropped to -3.08% while six-month performance rose 18.87%. The stock gained 9.37% in the past year, while it has gained 3.62% so far this year. A look at the trailing 12-month EPS for TEVA yields -1.98 with Next year EPS estimates of 2.43. For the next quarter, that number is 0.74. This implies an EPS growth rate of -8.52% for this year and 5.47% for next year. EPS is expected to grow by 1.60% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 33.47%.
Float and Shares Shorts:
At present, 1.12 billion TEVA shares are outstanding with a float of 1.12 billion shares on hand for trading. On Oct 30, 2023, short shares totaled 14.67 million, which was 1.56% higher than short shares on Sep 28, 2023. In addition to Mr. Eliyahu Sharon Kalif as the firm’s Executive VP & CFO, Mr. Eric Drape serves as its Executive Vice President of Global Operations.
Institutional Ownership:
Through their ownership of 49.63% of TEVA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.72% of TEVA, in contrast to 44.08% held by mutual funds. Shares owned by individuals account for 0.13%. As the largest shareholder in TEVA with 3.46% of the stake, Ion Asset Management holds 38,822,516 shares worth 38,822,516. A second-largest stockholder of TEVA, Excellence Investments Ltd., holds 34,481,692 shares, controlling over 3.08% of the firm’s shares. Lingotto Investment Management LL is the third largest shareholder in TEVA, holding 33,849,856 shares or 3.02% stake. With a 0.60% stake in TEVA, the American Funds Fundamental Invest is the largest stakeholder. A total of 6,727,432 shares are owned by the mutual fund manager. The iShares Tr. – Core MSCI EAFE ETF, which owns about 0.56% of TEVA stock, is the second-largest Mutual Fund holder. It holds 6,300,980 shares valued at 54.06 million. iShares Tr. – MSCI EAFE ETF holds 0.31% of the stake in TEVA, owning 3,506,571 shares worth 30.09 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TEVA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With TEVA analysts setting a high price target of $14.00 and a low target of $8.00, the average target price over the next 12 months is $10.63. Based on these targets, TEVA could surge 48.15% to reach the target high and fall by -15.34% to reach the target low. Reaching the average price target will result in a growth of 12.49% from current levels.
Summary of Insider Activity:
Insiders traded TEVA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 0 while 77,421 shares were sold.
